Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 7;17(4):374–444. doi: 10.1159/000539371

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Published by Elsevier BV on behalf of European Association for the Study of the Liver (EASL) and by S Karger AG.

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

PMC Copyright notice

Fig. 4. — Treatment recommendations beyond lifestyle modification in MASLD/MASH. The recommended choice of pharmacological treatment options in individuals with MASLD/MASH is dependent on comorbidities and stage of disease. BMI, body mass index; GLP1RA, glucagon-like peptide 1 receptor agonist; HCC, hepatocellular carcinoma; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; SGLT2, sodium-glucose cotransporter 2; T2D, type 2 diabetes.